These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34076896)

  • 1. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
    Brunner PM; Conrad C; Vender R; Grond S; Schuster C; Patel H; Xu W; Carrascosa Carrillo JM
    Br J Dermatol; 2021 Oct; 185(4):865-867. PubMed ID: 34076896
    [No Abstract]   [Full Text] [Related]  

  • 2. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
    Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
    J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García E; Herrera-Ceballos E
    Dermatol Ther; 2020 Nov; 33(6):e14202. PubMed ID: 32808703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.
    Georgakopoulos JR; Lam K; Sandhu VK; Ighani A; Phung M; Piguet V; Yeung J
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e416-e418. PubMed ID: 32176394
    [No Abstract]   [Full Text] [Related]  

  • 6. An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis.
    Puig L; Lomaga M; Hollister K; Dutronc Y; Berggren L; van de Kerkhof PCM
    Acta Derm Venereol; 2020 Dec; 100(19):adv00344. PubMed ID: 33236124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
    Valenzuela F; de la Cruz Fernandez C; Galimberti RL; Gürbüz S; McKean-Matthews M; Goncalves L; Romiti R
    Actas Dermosifiliogr; 2017; 108(6):550-563. PubMed ID: 28342534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
    Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN
    PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
    Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies.
    Blauvelt A; Ramharter M; Cohen AD; Xu W; Patel H; Schuster C; Riedl E; Puig L
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e828-e831. PubMed ID: 34310771
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
    Papp KA; Bachelez H; Blauvelt A; Winthrop KL; Romiti R; Ohtsuki M; Acharya N; Braun DK; Mallbris L; Zhao F; Xu W; Walls CD; Strober B
    Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 15. Ustekinumab Demonstrates Lower Uveitis Risk in Moderate to Severe Psoriasis Patients Compared with Tumor Necrosis Factor-α Inhibitors.
    Bang CH; Oh HJ; Kim YH; Jung JH; Lee JH; Park YM; Han JH
    Acta Derm Venereol; 2024 Sep; 104():adv34206. PubMed ID: 39248291
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
    Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
    J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Syed YY
    Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
    Blauvelt A; Gooderham M; Iversen L; Ball S; Zhang L; Agada NO; Reich K
    J Am Acad Dermatol; 2017 Nov; 77(5):855-862. PubMed ID: 28917383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.